Here are the S-3 shelf registrations from Summit Therapeutics Inc. (SMMT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow SMMT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SMMT filings page.
Summit Therapeutics Inc. filed a shelf registration on Form S-3 to permit offers and sales of common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights and units from time to time after the effective date.
The prospectus states the company’s common stock last traded at $14.11 per share on June 8, 2026, and discloses a going concern warning: management concluded there is substantial doubt about the company’s ability to continue as a going concern absent additional funding for the next twelve months. The prospectus reserves no specific aggregate offering amount and says net proceeds will be used for general corporate purposes, with specific terms to be provided in prospectus supplements.